Developer docs
API playgroundTry for free, no card

Search company profiles

Fuan Pharmaceutical Group

Full company profile

uuid003k4dt

Namestring
Fuan Pharmaceutical Group
Legal namestring
福安药业(集团)股份有限公司
Websiteurl
fapharm.com
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Fuan Pharmaceutical Group is a vertically integrated Chinese pharmaceutical manufacturer headquartered in Chongqing and listed on the Shenzhen Stock Exchange's ChiNext board (ticker: 300194.SZ) since 2011. Founded in 2004, the company produces active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms, with a product set that includes Gentamicin Sulfate, Aztreonam, Meropenem, and a growing range of injectable finished products. Operations are distributed across multiple Chinese subsidiaries — Yantai Justware, Ningbo Tianheng, Hubei Renmin, and Chongqing Bosheng Pharma — collectively employing 1,001–5,000 staff and maintaining multi-jurisdictional regulatory certifications (GMP, CEP, US DMF, Korea MFDS, India DCGI).

The company's revenue model is B2B, selling to hospitals, drug distributors, and international pharmaceutical manufacturers, with finished products and APIs exported to 70+ countries. Domestic volume is materially influenced by participation in China's national centralized drug procurement program, in which Fuan has been selected for both the 11th and 12th batches — a channel that secures baseline volume but compresses unit pricing. The company also pursues international expansion, including a US investment that has given rise to ongoing litigation as of 2026.

Financial performance has deteriorated materially. Revenue declined from $2.65B in 2023 to $2.39B in 2024 to $1.74B in 2025, with net income falling from $280M in 2024 to $77M in 2025 and EBITDA dropping from $534M to $311M over the same window. Despite this, Fuan has continued to invest in product expansion, securing drug registration certificates for Miku Chloride Injection and Polyol Injection in 2026-07, pursuing API capacity expansion at Bosheng Pharma (~173 tons/year), and receiving recognition on the 2026 Chemical R&D Top 100 and Chongqing Manufacturing Top 100 lists. Senior leadership turnover in 2026-07 (Deputy GM Feng Jing resignation) coincided with this period of revenue and earnings contraction.

Short descriptiontext

Fuan Pharmaceutical Group is a vertically integrated Chinese manufacturer of APIs, intermediates, and finished dosage forms, including Gentamicin Sulfate, Aztreonam, and Meropenem, serving hospitals, distributors, and international pharma manufacturers across 70+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersChongqing, China
HQ citystring
Chongqing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, active pharmaceutical ingredients, finished dosage forms, antibiotic manufacturing, pharmaceutical intermediates
Industry4 codes
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Finished Dosage Formulation Sales
TypeOne Time License
Description

Sale of manufactured pharmaceutical finished products including injections, tablets, capsules, and granules to hospitals, pharmacies, and distributors through direct sales and national centralized procurement tenders.

fapharm.com
2Active Pharmaceutical Ingredient (API) Sales
TypeOne Time License
Description

Production and sale of pharmaceutical raw materials including antibiotics, anti-tumor APIs, and specialty chemical drugs to domestic and international pharmaceutical manufacturers.

fapharm.com
3International Trade / Export
TypeOne Time License
Description

Export of APIs and formulations to international markets across Asia, Europe, and the Americas through dedicated international trade team.

fapharm.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fuan Pharmaceutical Group manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage formulations. Its portfolio spans therapeutic areas including antibiotics, anti-tumor, respiratory, and cardiovascular drugs, with multiple production subsidiaries across China and a presence in international markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Products exported to over 70 countries
+2 more records
Product overview1 text field

Fuan Pharmaceutical Group is a vertically integrated pharmaceutical manufacturer offering a comprehensive portfolio of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and finished dosage forms (injections, tablets, capsules, oral solutions). The company operates as a unified platform combining API production with downstream formulation manufacturing across multiple subsidiaries. Key product categories include antibiotics (Aztreonam, Gentamicin Sulfate, Meropenem), respiratory drugs (Doxofylline, Acetylcysteine), cardiovascular medications (Febuxostat, Levocetirizine), antiemetics (Granisetron, Ondansetron), neurological drugs (Piracetam, Citicoline), and oncology products. The company maintains GMP-certified manufacturing facilities and holds multiple international regulatory filings including US DMF, CEP, and certifications from India, Korea, and Japan.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chinese pharmaceutical company with API manufacturing and specialty finished formulations including oncology and injectable products; comparable to Fuan in formulation manufacturing capabilities and participation in national procurement.

2Northeast Pharmaceutical Group
TypeDirect peer
Description

Chinese API and finished dosage form manufacturer with strong antibiotics franchise and centralized procurement participation; directly comparable to Fuan's antibiotic API and formulation capabilities, particularly gentamicin sulfate and other aminoglycoside products.

TypeDirect peer
Description

Major Chinese generic pharmaceutical manufacturer with strong API and finished formulation operations, including antibiotics and injectable products; directly comparable to Fuan's manufacturing portfolio and centralized procurement strategy.

4Zhejiang Hisun Pharmaceutical
TypeDirect peer
Description

Major Chinese API manufacturer with significant finished formulation business and extensive international API export registrations including US DMF and CEP; closely comparable to Fuan's Yantai Justware gentamicin sulfate export franchise and broader API/formulation portfolio.

TypeBroad incumbent
Description

Large private Chinese pharmaceutical manufacturer with vertically integrated API and formulation operations across antibiotics, cardiovascular, and oncology; comparable to Fuan in therapeutic area breadth and procurement participation, though at significantly larger scale.

TypeDirect peer
Description

One of China's largest vertically integrated pharmaceutical manufacturers with API and finished formulation operations across antibiotics, cardiovascular, and oncology; comparable to Fuan in its API-to-formulation value chain and participation in national centralized procurement.

7Jiangsu Hengrui Medicine
TypeBroad incumbent
Description

One of China's leading innovative and generic pharmaceutical manufacturers with extensive injectable and API operations; overlaps with Fuan in injectable formulations and centralized procurement, though Hengrui's innovation pipeline is substantially larger.

8Shanghai Pharmaceuticals Holding
TypeBroad incumbent
Description

One of China's largest pharmaceutical groups spanning API production, formulation manufacturing, distribution, and retail pharmacy; comparable to Fuan in API and formulation manufacturing but with broader distribution and retail integration.

9China Resources Pharmaceutical Group
TypeBroad incumbent
Description

State-owned pharmaceutical conglomerate covering API manufacturing, formulations, and distribution across multiple therapeutic areas; overlaps with Fuan in generic pharmaceutical manufacturing and national procurement participation, but operates at materially larger scale.

10Tianjin Pharmaceutical Group
TypeDirect peer
Description

Chinese state-affiliated pharmaceutical manufacturer with API production and finished dosage form operations across therapeutic categories; comparable to Fuan's vertically integrated manufacturing model and domestic B2B sales channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fuan Pharmaceutical Group

Generic Pharmaceuticals Manufacturingfapharm.com

Fuan Pharmaceutical Group is a vertically integrated Chinese manufacturer of APIs, intermediates, and finished dosage forms, including Gentamicin Sulfate, Aztreonam, and Meropenem, serving hospitals, distributors, and international pharma manufacturers across 70+ countries.

What Fuan Pharmaceutical Group does

Fuan Pharmaceutical Group is a vertically integrated Chinese pharmaceutical manufacturer headquartered in Chongqing and listed on the Shenzhen Stock Exchange's ChiNext board (ticker: 300194.SZ) since 2011. Founded in 2004, the company produces active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms, with a product set that includes Gentamicin Sulfate, Aztreonam, Meropenem, and a growing range of injectable finished products. Operations are distributed across multiple Chinese subsidiaries — Yantai Justware, Ningbo Tianheng, Hubei Renmin, and Chongqing Bosheng Pharma — collectively employing 1,001–5,000 staff and maintaining multi-jurisdictional regulatory certifications (GMP, CEP, US DMF, Korea MFDS, India DCGI).

The company's revenue model is B2B, selling to hospitals, drug distributors, and international pharmaceutical manufacturers, with finished products and APIs exported to 70+ countries. Domestic volume is materially influenced by participation in China's national centralized drug procurement program, in which Fuan has been selected for both the 11th and 12th batches — a channel that secures baseline volume but compresses unit pricing. The company also pursues international expansion, including a US investment that has given rise to ongoing litigation as of 2026.

Financial performance has deteriorated materially. Revenue declined from $2.65B in 2023 to $2.39B in 2024 to $1.74B in 2025, with net income falling from $280M in 2024 to $77M in 2025 and EBITDA dropping from $534M to $311M over the same window. Despite this, Fuan has continued to invest in product expansion, securing drug registration certificates for Miku Chloride Injection and Polyol Injection in 2026-07, pursuing API capacity expansion at Bosheng Pharma (~173 tons/year), and receiving recognition on the 2026 Chemical R&D Top 100 and Chongqing Manufacturing Top 100 lists. Senior leadership turnover in 2026-07 (Deputy GM Feng Jing resignation) coincided with this period of revenue and earnings contraction.

Fuan Pharmaceutical Group firmographics

Firmographics
Name
Fuan Pharmaceutical Group
Legal name
福安药业(集团)股份有限公司
Website
https://fapharm.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Fuan Pharmaceutical Group is a vertically integrated Chinese manufacturer of APIs, intermediates, and finished dosage forms, including Gentamicin Sulfate, Aztreonam, and Meropenem, serving hospitals, distributors, and international pharma manufacturers across 70+ countries.
Ownership category
akta.pro rank

Fuan Pharmaceutical Group industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Active pharmaceutical ingredients
  • Finished dosage forms
  • Antibiotic manufacturing
  • Pharmaceutical intermediates

Where Fuan Pharmaceutical Group is headquartered

Location

Headquarters

HQ city
Chongqing
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Fuan Pharmaceutical Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Finished Dosage Formulation Sales: Sale of manufactured pharmaceutical finished products including injections, tablets, capsules, and granules to hospitals, pharmacies, and distributors through direct sales and national centralized procurement tenders.
  2. Active Pharmaceutical Ingredient (API) Sales: Production and sale of pharmaceutical raw materials including antibiotics, anti-tumor APIs, and specialty chemical drugs to domestic and international pharmaceutical manufacturers.
  3. International Trade / Export: Export of APIs and formulations to international markets across Asia, Europe, and the Americas through dedicated international trade team.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Fuan Pharmaceutical Group product offering

Product offering

Core offering

Fuan Pharmaceutical Group manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage formulations. Its portfolio spans therapeutic areas including antibiotics, anti-tumor, respiratory, and cardiovascular drugs, with multiple production subsidiaries across China and a presence in international markets.

Product overview

Fuan Pharmaceutical Group is a vertically integrated pharmaceutical manufacturer offering a comprehensive portfolio of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and finished dosage forms (injections, tablets, capsules, oral solutions). The company operates as a unified platform combining API production with downstream formulation manufacturing across multiple subsidiaries. Key product categories include antibiotics (Aztreonam, Gentamicin Sulfate, Meropenem), respiratory drugs (Doxofylline, Acetylcysteine), cardiovascular medications (Febuxostat, Levocetirizine), antiemetics (Granisetron, Ondansetron), neurological drugs (Piracetam, Citicoline), and oncology products. The company maintains GMP-certified manufacturing facilities and holds multiple international regulatory filings including US DMF, CEP, and certifications from India, Korea, and Japan.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Products exported to over 70 countries
  • +2 more outcomes

Companies that use Fuan Pharmaceutical Group

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Fuan Pharmaceutical Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Fuan Pharmaceutical Group partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Fuan Pharmaceutical Group competitors and assessment

Company assessment

Direct peers

  • Luye Pharma Group: Chinese pharmaceutical company with API manufacturing and specialty finished formulations including oncology and injectable products; comparable to Fuan in formulation manufacturing capabilities and participation in national procurement.
  • Northeast Pharmaceutical Group: Chinese API and finished dosage form manufacturer with strong antibiotics franchise and centralized procurement participation; directly comparable to Fuan's antibiotic API and formulation capabilities, particularly gentamicin sulfate and other aminoglycoside products.
  • Qilu Pharmaceutical: Major Chinese generic pharmaceutical manufacturer with strong API and finished formulation operations, including antibiotics and injectable products; directly comparable to Fuan's manufacturing portfolio and centralized procurement strategy.
  • Zhejiang Hisun Pharmaceutical: Major Chinese API manufacturer with significant finished formulation business and extensive international API export registrations including US DMF and CEP; closely comparable to Fuan's Yantai Justware gentamicin sulfate export franchise and broader API/formulation portfolio.
  • CSPC Pharmaceutical Group: One of China's largest vertically integrated pharmaceutical manufacturers with API and finished formulation operations across antibiotics, cardiovascular, and oncology; comparable to Fuan in its API-to-formulation value chain and participation in national centralized procurement.
  • Tianjin Pharmaceutical Group: Chinese state-affiliated pharmaceutical manufacturer with API production and finished dosage form operations across therapeutic categories; comparable to Fuan's vertically integrated manufacturing model and domestic B2B sales channels.

Broad incumbents

  • Yangtze River Pharmaceutical Group: Large private Chinese pharmaceutical manufacturer with vertically integrated API and formulation operations across antibiotics, cardiovascular, and oncology; comparable to Fuan in therapeutic area breadth and procurement participation, though at significantly larger scale.
  • Jiangsu Hengrui Medicine: One of China's leading innovative and generic pharmaceutical manufacturers with extensive injectable and API operations; overlaps with Fuan in injectable formulations and centralized procurement, though Hengrui's innovation pipeline is substantially larger.
  • Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical groups spanning API production, formulation manufacturing, distribution, and retail pharmacy; comparable to Fuan in API and formulation manufacturing but with broader distribution and retail integration.
  • China Resources Pharmaceutical Group: State-owned pharmaceutical conglomerate covering API manufacturing, formulations, and distribution across multiple therapeutic areas; overlaps with Fuan in generic pharmaceutical manufacturing and national procurement participation, but operates at materially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Fuan Pharmaceutical Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fuan Pharmaceutical Group leadership team

Management profile

Number of profiles

Profiles3 records

Fuan Pharmaceutical Group subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Fuan Pharmaceutical Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fuan Pharmaceutical Group M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fuan Pharmaceutical Group

What does Fuan Pharmaceutical Group do?

Fuan Pharmaceutical Group manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage formulations. Its portfolio spans therapeutic areas including antibiotics, anti-tumor, respiratory, and cardiovascular drugs, with multiple production subsidiaries across China and a presence in international markets.

Is Fuan Pharmaceutical Group a public or private company?

Fuan Pharmaceutical Group is a public company. It is classified as public and is currently operating.

When was Fuan Pharmaceutical Group founded?

Fuan Pharmaceutical Group was founded in 2004. It employs 1,001 to 5,000 people.

Where is Fuan Pharmaceutical Group based?

Fuan Pharmaceutical Group is headquartered in Chongqing, China, in the Asia region.

How does Fuan Pharmaceutical Group make money?

Three revenue lines are on record. Finished Dosage Formulation Sales are the primary driver. The others are active Pharmaceutical Ingredient (API) Sales and international Trade / Export.

Who are Fuan Pharmaceutical Group's main competitors?

Direct peers on record are Luye Pharma Group, Northeast Pharmaceutical Group, Qilu Pharmaceutical, Zhejiang Hisun Pharmaceutical, CSPC Pharmaceutical Group and Tianjin Pharmaceutical Group. Broad incumbents are Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, Shanghai Pharmaceuticals Holding and China Resources Pharmaceutical Group.

Does Fuan Pharmaceutical Group have an API?

No public API is recorded for Fuan Pharmaceutical Group.

What industry is Fuan Pharmaceutical Group in?

Fuan Pharmaceutical Group's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooFuan Pharmaceutical (300194.SZ) subsidiary's cefditoren pivoxil granules included in National Reimbursement Drug ListFuan Pharmaceutical's subsidiary added cefditoren pivoxil granules to the National Medical Insurance Catalogue, with reimbursement rates of RMB 4.02 and RMB 5.94 per bag for 30mg and 50mg doses, effective January 1, 2027, to December 31, 2028. The product treats bacterial skin infections and related conditions.MoomooFuan Pharmaceutical (300194.SZ) announced its financial results for the first three quarters, with net profit attributable to shareholders of the parent company reaching RMB 124 million, a year-on-year decrease of 25.41%.Fuan Pharmaceutical reported Q3 2026 results for the first three quarters, with operating revenue of RMB 1.225 billion, down 6.9% year over year. Net profit attributable to shareholders was RMB 124 million, a 25.41% decline, primarily due to an RMB 88 million drop in investment income from associate Fumin Bank. Excluding this, core business profit rose 71.78% to RMB 111 million.JiemianFuan Pharmaceutical: Vice President Feng Jing resigned due to work adjustment reasons.Fuan Pharmaceutical announced on July 2 that Deputy General Manager Feng Jing submitted a written resignation letter citing work adjustment reasons. The resignation became effective upon delivery to the board of directors. Following departure, Feng Jing will no longer hold any position within the company.openPR.comFuture of Global Sulindac Tablets Market Research Report: Key Players, Market Insights with Forecast 2025-2033The global Sulindac Tablets market was valued at US$0.68 billion in 2024 and is projected to reach US$1.1 billion by 2033, a CAGR of 8.5%. The report covers market segments by type and application, and profiles key manufacturers including Fuan Pharmaceutical Group, Ningbo Tianheng, and Chia Tai Pharmaceutical.